Zdravka Medarova

Company: TransCode Therapeutics

Job title: Chief Technology Officer & Co-Founder

Seminars:

Clinical Experience with a First-in-Class ASO Against miR-10b for the Treatment of Metastatic Cancer 11:00 am

In early discovery efforts, miRNA-10b was identified as a master regulator of the viability of metastatic tumor cells and we developed a therapeutic strategy based on miR-10b inhibition The specific inhibition of miR-10b was achieved using ASOs delivered to metastatic sites by TransCode’s proprietary delivery system (termed TTX-MC138). On the path to clinical development of…Read more

day: Conference Day Two

Seizing the Value of RNAi Therapeutics for Oncology to Develop Precise, Effective Treatments for Patients 2:00 pm

RNAi therapeutics holds promise for treating complex genetic diseases such as cancer by targeting multiple oncogenes, but release of the therapeutic payload must be rapid and precise, and the heterogeneity of tumors must be considered. Therefore, this Workshop will address: How to identify genetic targets in heterogenous tumors to increase correlation in response at the…Read more

day: Pre-Conference Workshop Day